US4558006A
Expired / Lapsed
US
⏱️ 0.0 years remaining
A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
Assignee: Amgen K A Inc
•
Filing: 1983-02-04
•
Granted: 1985-12-10
•
Expires: 2003-02-04
Abstract
Abstract Disclosed is a new mouse-mouse hybridoma tumor cell line A.T.C.C. No. HB8209. A monoclonal antibody produced by said cell line is specifically immunologically reactive with erythropoietin and with a polypeptide whose amino acid sequence is substantially duplicative of a sequence extant is erythropoietin. Disclosed also are procedures for isolation of erythropoietin by affinity purification and for quantitative detection of erythropoietin in fluid samples.
Inventors
- 👤 Joan C. Egrie
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 05:16
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/22; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/74; G01N33/746; Y; Y10; Y10S; Y10S435/00; Y10S435/803; Y10S435/8215; Y10S435/948; Y10S436/00; Y10S436/815; Y10S436/817; Y10S436/824; Y10S530/00; Y10S530/808; Y10S530/809
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
33 words
As a new composition, a hybridoma cell line A.T.C.C. HB8209 that produces a monoclonal antibody specifically immunoreactive with erythropoietin and with a polypeptide substantially duplicative of an amino acid sequence extant in erythropoietin.
Claim 2
Dependent Claim
33 words
As a new composition, a hybridoma cell line A.T.C.C. HB8209 that produces a monoclonal antibody specifically immunoreactive with erythropoietin and with a polypeptide substantially duplicative of an amino acid sequence extant in erythropoietin.
Claim 3
Dependent Claim
33 words
As a new composition, the monoclonal antibody produced from hybridoma cell line ATCC HB8209 and specifically immunoreactive with erythropoietin and with a polypeptide substantially duplicative of an amino acid sequence extant in erythropoietin.
Claim 4
Dependent Claim
33 words
As a new composition, the monoclonal antibody produced from hybridoma cell line ATCC HB8209 and specifically immunoreactive with erythropoietin and with a polypeptide substantially duplicative of an amino acid sequence extant in erythropoietin.
Claim 5
Dependent Claim
62 words
The process of isolating biologically active erythropoietin from a biological fluid comprising contacting a biological fluid containing erythropoietin with the monoclonal antibody produced from hybridoma cell line ATCC HB8209 and specifically immunoreactive with erythropoietin and with a polypeptide substantially duplicative of an amino acid sequence extant in erythroopietin for an immunological reaction and isolating the biologically active erythropoietin from said biological fluid.
Claim 6
Dependent Claim
62 words
The process of isolating biologically active erythropoietin from a biological fluid comprising contacting a biological fluid containing erythropoietin with the monoclonal antibody produced from hybridoma cell line ATCC HB8209 and specifically immunoreactive with erythropoietin and with a polypeptide substantially duplicative of an amino acid sequence extant in erythroopietin for an immunological reaction and isolating the biologically active erythropoietin from said biological fluid.
Claim 7
Dependent Claim
12 words
The process of claim 3 wherein said fluid is a human fluid.
Claim 8
Dependent Claim
24 words
The process of claim 3 wherein said fluid is selected from the group consisting of whole blood, serum, urine, cystic fluid and cerebrospinal fluid.
Claim 9
Dependent Claim
72 words
The process for the quantitative detection of erythropoeitin in a biological fluid comprising contacting a biological fluid with the monoclonal antibody produced from hybridoma cell line ATCC HB8209 and specifically immunoreactive with erythropoietin and with a polypeptide substantially duplicative of an amino acid sequence extant in erythropoietin so the erythropoietin binds to said antibody and measuring the amount of bound antibody as a measure of the amount of erythropoietin in said fluid.
Claim 10
Dependent Claim
72 words
The process for the quantitative detection of erythropoeitin in a biological fluid comprising contacting a biological fluid with the monoclonal antibody produced from hybridoma cell line ATCC HB8209 and specifically immunoreactive with erythropoietin and with a polypeptide substantially duplicative of an amino acid sequence extant in erythropoietin so the erythropoietin binds to said antibody and measuring the amount of bound antibody as a measure of the amount of erythropoietin in said fluid.
Claim 11
Dependent Claim
12 words
The process of claim 6 wherein said fluid is a human fluid.
Claim 12
Dependent Claim
24 words
The process of claim 6 wherein said fluid is selected from the group consisting of whole blood, serum, urine, cystic fluid and cerebrospinal fluid.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-12-09 | 1989-06-10 | 1989-12-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-12-09 | 1993-06-10 | 1993-12-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-12-09 | 1997-06-10 | 1997-12-10 | $7700.00 | Window Closed / Lapsed |